FilingsTodayWhanin Pharm
At a glance
Whanin Pharm filed 23 disclosures in the last 12 months, including 3 earnings, 2 buyback and 1 5% holder. The most recent key filing was on Oct 29: Operating profit ₩7.5B, up 111.8% YoY. Revenue ₩71.6B, up 8.9% YoY.
Revenue for 2025 was ₩255B, down 1.7% on 2024. Operating margin was 5.1% against 8.3% a year earlier. Debt was 14% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩143B and operating profit of ₩17.3B.
The 2025 annual report lists 671 employees with an average tenure of 6.3 years and average pay of ₩75.3M, #474 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩312M each on average. It paid ₩300 per common share in cash dividends, against ₩300 a year earlier (+0%). 이원범 and related parties held 23.27% at year end.
From the 2025 annual report
Staff: 671 (424 men, 247 women), of whom 32 on fixed-term contracts. Total pay for the year: ₩50.5B. Directors and auditors: 5, paid ₩1.6B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩300 | ₩300 | ₩300 |
| Payout ratio | 40.8% | 19.6% | 15.4% |
| Yield (as filed) | 2.58% | 2.49% | 2.02% |
| Total cash dividends | ₩5.5B | ₩4.6B | ₩4.6B |
Largest shareholder
이원범 holds 13.27%; with 1 related party the group holds 23.27% of common shares at year end.
Individuals paid ₩500M or more
| 이광식 대표이사 회장 | ₩936M |
| 이원범 대표이사 사장 | ₩533M |
Auditor: 삼정회계법인 · opinion: Unqualified.
Rankings: Low debt #65 of 1,372
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.